MIDDLETOWN, Pa.—MacuLogix, Inc., a company that equips eyecare professionals with the instruments, tools and education to diagnose and treat patients with age-related macular degeneration (AMD), announced its new Optometric Advisory Board. Seven clinical advisors were appointed to provide strategic input on key initiatives and serve as company ambassadors at industry events and in the media.

The MacuLogix Optometric Clinical Advisors are:
Glenn S. Corbin, OD – Wyomissing Optometric Center, Wyomissing, Pennsylvania
Steven G. Ferrucci, OD, FAAO – Sepulveda VA Hospital, Sepulveda, California
Jeffry D. Gerson, OD, FAAO – Grin Eye Care, Olathe, Kansas
Paul M. Karpecki, OD, FAAO – Kentucky Eye Institute, Lexington, Kentucky
Gary S. Kirman, OD – Kirman Eye, Hummelstown, Pennsylvania
Pamela Lowe, OD, FAAO – Professional Eye Care Center, Niles, Illinois
Laurie Sorrenson, OD, FAAO – Lakeline Vision Center, Cedar Park, Texas.

The Optometric Advisory Board, which is led by Maculogix co-founder and chief technology officer Greg Jackson, PhD, is currently tasked with documenting standard of care guidelines for the treatment of AMD. The final consensus paper, scheduled to be published this fall, will outline essential, practical steps that optometrists can reference in everyday clinical practice.

“We are very excited to partner with these industry leaders and AdaptDx super-users to help us achieve our vision of eliminating blindness caused by age-related macular degeneration,” said William McPhee, president and CEO of MacuLogix. “Each advisor is an early adopter of technology and their collective experiences are helping us drive the greater adoption of the AdaptDx.”

To learn more about each Clinical Advisor, visit www.maculogix.com/clinical-advisors.